Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + nab-paclitaxel + S-1 first-line study in advanced gastric/GEJ adenocarcinoma
ChiCTR2300069672Phase 4Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, paclitaxel and tegafur in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Henan Cancer Hospital. Primary endpoint: Objective response rate. Started Sep 2020; status: recruiting.
02
Drugs
camrelizumabpaclitaxeltegafur
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300069672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069672.